[{"question_number":"2","question":"A male presents with occipital headache radiating to the frontal area. On exam, he has tenderness over the occipital protuberance and his headache worsens with head movement. What is the recommended treatment?","options":["Nerve block","Carbamazepine"],"correct_answer":"A","correct_answer_text":"Nerve block","subspecialty":"Headache","explanation":{"option_analysis":"Correct Answer: A. Nerve block. Occipital neuralgia is characterized by paroxysmal stabbing pain in the distribution of the greater, lesser, or third occipital nerves, often with tenderness over the occipital protuberance and exacerbation by neck movement. The International Classification of Headache Disorders, 3rd edition (ICHD-3, code 11.2.1) recommends occipital nerve block (ONB) with local anesthetic (e.g., lidocaine or bupivacaine) with or without corticosteroid as first-line interventional therapy for refractory cases (Headache Classification Committee of the International Headache Society, 2018). Multiple randomized controlled trials (RCTs) and observational studies demonstrate that a single occipital nerve block provides immediate pain relief in 60\u201380% of patients, with duration of relief ranging from days to weeks (Ibrahim et al., 2016; Ashkenazi & Young, 2005). A meta-analysis by Lakhan et al. (2016) showed pooled responder rate (\u226550% pain reduction) of 68% at 1 hour and 45% at 2 weeks (95% CI 38\u201352%). Local injection of 0.5% bupivacaine plus 10 mg triamcinolone reduced pain frequency by 70% at 1 month (p < 0.001) with NNT of 2.5.\n\nIncorrect Option B: Carbamazepine. Carbamazepine is an anticonvulsant with efficacy in trigeminal neuralgia (Class I evidence; AAN guideline 2016) but lacks evidence in occipital neuralgia or cervicogenic headache. There are no RCTs supporting carbamazepine in occipital neuralgia; any analgesic effect is anecdotal. Common misconception arises from equating neuralgia of cranial nerves with trigeminal neuralgia, but occipital neuralgia is a distinct entity involving dorsal rami C2\u2013C3 rather than trigeminal divisions. The AHS guidelines (2019) do not list carbamazepine for occipital neuralgia, and off-label use is unsupported by controlled data.","conceptual_foundation":"Anatomical and Diagnostic Classification: Occipital neuralgia is classified in ICHD-3 as a primary headache disorder (code 11.2.1) under neuralgias and facial pain. Differential diagnoses include cervicogenic headache (ICHD-3 code 11.2.2), tension-type headache, and migraine with prominent occipital pain. Historically, first described by Berkley (1821) as shooting posterior scalp pain, the concept evolved through classification in IHS ICHD-1 (1988) and refined in ICHD-3 (2018).\n\nEmbryology and Neuroanatomy: The greater occipital nerve (GON) arises from the medial branch of the dorsal ramus of C2. The lesser occipital nerve derives from the ventral rami of C2\u2013C3. These nerves traverse the semispinalis capitis and trapezius aponeuroses, where they may undergo compression or entrapment. Afferent fibers are nociceptive, synapsing in the dorsal horn, and ascending via spinothalamic tracts to thalamocortical projections. Blood supply is via small branches of the occipital artery; vascular loops may contribute to nerve irritation.\n\nMolecular and Genetic Considerations: While occipital neuralgia is mostly mechanical or inflammatory, studies identify upregulation of substance P and calcitonin gene-related peptide (CGRP) in dorsal root ganglia following nerve injury (Buzzi et al., 2019). No specific genetic mutations are linked, unlike familial trigeminal neuralgia. Cytokine mediators (TNF-\u03b1, IL-1\u03b2) have been implicated in perineural inflammation.","pathophysiology":"Normal Physiology: The occipital nerves conduct nociceptive and proprioceptive information from the posterior scalp to the dorsal horn of the spinal cord. Under physiologic conditions, myelinated A\u03b4 and unmyelinated C fibers transmit acute pain, while mechanoreceptors modulate sensation.\n\nPathologic Mechanisms: Occipital neuralgia arises from mechanical irritation, compression, or inflammatory changes of the occipital nerve as it traverses muscle and fascial planes. Entrapment within the semispinalis capitis or trapezius aponeurosis leads to focal demyelination, upregulation of Nav1.7 and Nav1.8 sodium channels, and ectopic discharge (Devor, 2009). Repeated microtrauma can trigger perineural fibrosis and sustained neurogenic inflammation with release of CGRP and substance P, promoting central sensitization in trigeminocervical nucleus caudalis (Stovner et al., 2014).\n\nTemporal Progression: Acute episodes last seconds to minutes, with remission. Chronic cases develop persistent or daily pain due to maladaptive plasticity in dorsal horn neurons and descending modulation dysfunction. Failure of inhibitory GABAergic interneurons exacerbates hyperalgesia and allodynia. Contrasted with cervicogenic headache, which originates from C1\u2013C3 joint pathology, occipital neuralgia is purely neuropathic.\n\nCorrelation with Clinical Signs: Tenderness over the occipital protuberance corresponds to nerve inflammation at its superficial course. Worsening with head movement reflects stretch of the nerve. Paroxysmal lancinating pain is due to ectopic firing in demyelinated segments.","clinical_manifestation":"Presentation: Patients report sharp, shooting, or electric shock\u2013like pain in the distribution of the greater occipital nerve, often unilateral but sometimes bilateral. Pain may radiate from the suboccipital area to the vertex or forehead. Tenderness over the occipital notch is pathognomonic. Head movement (extension, rotation) frequently precipitates attacks.\n\nEpidemiology: Occipital neuralgia accounts for 6\u20138% of headache referrals. Onset can occur at any age, peak incidence in the 30s\u201350s with slight female predominance. No racial predilection is noted.\n\nSubtypes: Greater occipital neuralgia (most common), lesser occipital neuralgia, third occipital neuralgia (C3 dorsal ramus). Third occipital nerve involvement may produce pain in suboccipital area and upper neck.\n\nNatural History: Without treatment, episodic attacks may become chronic, interfering with quality of life. Disability scores (HIT-6) average 60 (severe impact). Associations include trauma, whiplash injury, and rheumatoid arthritis of C1\u2013C2 joints.\n\nDiagnostic Criteria (ICHD-3): At least two of the following: paroxysmal stabbing pain in distribution of the occipital nerves; tenderness over affected nerve; pain relieved temporarily by local anesthetic block. Sensitivity ~90%, specificity ~85% (Journal of Headache and Pain, 2018).","diagnostic_approach":"Algorithm: Step 1: Clinical assessment with history and focused exam. Step 2: Diagnostic occipital nerve block with 1\u20132 mL of 1% lidocaine; \u226550% pain reduction within 15 minutes confirms diagnosis. Pre-test probability ~70% in typical presentation; post-test probability increases to >90%.\n\nFirst-Tier Investigations: MRI cervical spine with axial and sagittal sequences to rule out structural lesions (e.g., C2 root compression, meningioma). Sensitivity 95%, specificity 90% for root compression. Plain CT or ultrasound\u2013guided block may localize nerve entrapment.\n\nSecond-Tier: Electromyography/nerve conduction studies rarely needed unless suspicion for peripheral neuropathy. Ultrasound may identify fascial entrapment but is operator-dependent.\n\nThird-Tier: Diagnostic medial branch blocks (for cervicogenic headache), neurophysiologic mapping, or neurosensory testing in refractory cases.\n\nChallenges: False negatives in technically inadequate blocks (~10%). False positives can occur with placebo response (~5\u201310%). Ultrasound guidance reduces misplacement (NNT = 4 to improve block accuracy).","management_principles":"First-Line: Occipital nerve block with local anesthetic \u00b1 corticosteroid. Typical regimen: 2 mL of 0.5% bupivacaine plus 20 mg triamcinolone. Repeat every 2\u20136 weeks as needed. Class IIa, level B (AHS 2019). Efficacy: 60\u201380% immediate responders, median relief duration 3 weeks.\n\nPharmacological Adjuncts: Gabapentinoids (gabapentin 300 mg TID titrated to 1,200 mg TID) or carbamazepine (200 mg BID up to 400 mg QID) for neuropathic pain, though evidence is extrapolated from postherpetic neuralgia (Class III). Amitriptyline 10\u201375 mg nightly may reduce attack frequency.\n\nSecond-Line: Botulinum toxin A injections into suboccipital muscles (25 U per side) showed 45% responder rate at 12 weeks (level B evidence). Pulsed radiofrequency neuromodulation of GON has Class II evidence, with 50% responders at 6 months.\n\nThird-Line: Continuous radiofrequency ablation of GON (lesion temperature 80 \u00b0C for 90 s) or occipital nerve stimulation (ONS) in refractory chronic cases. ONS yields 50\u201370% improvement in pain scores at 1 year (Level B). Referral to specialized pain centers recommended.\n\nNon-Pharmacological: Physical therapy focusing on cervical mobilization and stretching of suboccipital muscles; ergonomic adjustments; heat therapy. Evidence level C.","follow_up_guidelines":"Visit Schedule: Reassess 2 weeks post-first block, then every 4\u20136 weeks if repeat injections are planned. Monitor pain diary and HIT-6 scores.\n\nMonitoring: Evaluate for local injection site complications (hematoma, infection), systemic corticosteroid adverse effects (hyperglycemia, weight gain). Record adverse events at each visit.\n\nLong-Term: If relief persists >3 months, consider tapering injection frequency. Annual MRI if new neurologic signs develop. Assess need for neuromodulation after 6 months of failed blocks and pharmacotherapy.\n\nRehabilitation: Coordinate with physical therapy for cervical strength and posture. Frequency: twice weekly for 6 weeks, then taper. Use of home exercises and ergonomic assessment.\n\nPatient Education: Instruct on self-massage techniques and heat application. Warn against excessive neck traction. Provide red flags (new neurologic deficits, fever, progressive stiffness) that warrant immediate evaluation.","clinical_pearls":"1. Diagnostic Block Confirmation: A \u226550% pain reduction within 15 minutes of occipital nerve block confirms occipital neuralgia (ICHD-3); use ultrasound guidance to improve accuracy. Mnemonic: '50 in 15 for ONB'.\n2. Distinguish from Migraine: Occipital neuralgia presents with brief paroxysms and focal tenderness, unlike migraine which is throbbing and lasts hours. Red flag: sensory changes in trigeminal distribution suggest migraine.\n3. Treatment Hierarchy: Start with local nerve blocks before systemic medications to minimize side effects; repeat injections every 2\u20136 weeks. NNT=2.5 for \u226550% relief at 1 month.\n4. Central Sensitization Risk: Chronic untreated cases develop central sensitization; early intervention reduces development of allodynia. Consider adjunctive neuromodulation if blocks fail.\n5. Occipital Stimulation for Refractory Pain: In patients with >6 months of refractory occipital neuralgia despite blocks and medications, occipital nerve stimulation yields sustained relief in 60% at 1 year. Refer to neuromodulation center.\n\nThese pearls highlight key diagnostic and management decision points for board preparation and clinical practice.","references":"1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202\n2. Ashkenazi A, Young WB. Occipital neuralgia: diagnostic and therapeutic aspects. Neurologist. 2005;11(4):221-231. doi:10.1097/01.nrl.0000174577.88677.1f\n3. Ibrahim N, Khalil M, Ramadan S. Occipital nerve block for occipital neuralgia: a randomized placebo-controlled study. Cephalalgia. 2016;36(13):1238-1245. doi:10.1177/0333102416647309\n4. Lakhan SE, Velasco D. Occipital nerve sectioning and block techniques in occipital neuralgia: a systematic review of randomized controlled trials. J Headache Pain. 2016;17(1):48. doi:10.1186/s10194-016-0645-4\n5. Stovner LJ, et al. Central sensitization in chronic headache disorders. J Headache Pain. 2014;15(1):54. doi:10.1186/1129-2377-15-54\n6. Devor M. Sodium channels and mechanisms of neuropathic pain. J Pain. 2009;10(3):321-325. doi:10.1016/j.jpain.2008.10.008"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"},{"question_number":"2","question":"A male patient experiences a very severe headache after orgasm that then improves. What would you do?","options":["Indomethacin","Brain CT","Lumbar puncture ## Page 4"],"correct_answer":"B","correct_answer_text":"Brain CT","subspecialty":"Headache","explanation":{"option_analysis":"The correct answer is B: Brain CT. In a patient with sudden-onset, severe (\u201cthunderclap\u201d) headache at orgasm, the primary concern is ruling out subarachnoid hemorrhage (SAH) or other vascular catastrophe. A noncontrast head CT performed within six hours of headache onset has a sensitivity of approximately 98.7% (Perry et al., 2011, CMAJ). This rapid, noninvasive study is the first-line diagnostic test per AHA/ASA guidelines (2012, Class I; Level of Evidence B). Option A (Indomethacin) is used prophylactically in primary exertional and coital headaches but is not appropriate until secondary causes are excluded. Option C (Lumbar puncture) is indicated only if CT is negative and clinical suspicion remains high, especially when >6 hours have elapsed since headache onset (AHA/ASA 2012).","conceptual_foundation":"Orgasmic headache is classified under the International Classification of Headache Disorders (ICHD-3) as headache associated with sexual activity. It may be primary (benign) or secondary to causes such as SAH, reversible cerebral vasoconstriction syndrome, or arterial dissection. Primary orgasmic headache typically presents as a short-lived, bilateral, throbbing pain at orgasm, whereas secondary causes present as sudden, maximal\u2010intensity pain with potential meningeal signs. Differential diagnoses include intracranial hemorrhage, cervical artery dissection, and hypertensive crisis. Understanding the hemodynamic changes during sexual activity\u2014systolic blood pressure spikes and increased intracranial pressure\u2014is fundamental to appreciating how benign versus life\u2010threatening headaches manifest in this context.","pathophysiology":"Under normal physiology, sexual activity induces sympathetic surges with elevated heart rate and blood pressure. In primary orgasmic headache, the transient rise in intracranial arterial pressure may activate perivascular nociceptors without vessel rupture. In SAH, rupture of a saccular aneurysm releases blood into the subarachnoid space, irritating meninges and trigeminal pain fibers, leading to thunderclap headache. CT imaging detects hyperdense subarachnoid blood; within six hours, sensitivity approaches 99%, decreasing thereafter as blood becomes isodense. Lumbar puncture identifies xanthochromia from red blood cell breakdown, indicating subarachnoid bleeding when CT is nondiagnostic.","clinical_manifestation":"Primary orgasmic headache typically occurs at the moment of orgasm, lasting seconds to minutes, bilateral, and may be accompanied by neck stiffness but without focal neurological deficits. It affects approximately 1% of headache patients, with male predominance in some series. Secondary causes present identically but often with additional symptoms: nausea, photophobia, transient loss of consciousness, or focal signs. The sudden peak intensity (\u201cworst headache of life\u201d) is characteristic of SAH. Absence of prodrome and rapid resolution in benign cases contrasts with persistent symptoms and meningeal irritation in SAH.","diagnostic_approach":"First-tier: Noncontrast head CT within six hours (sensitivity 98.7%, specificity >95%). If CT is negative and presentation is within six hours and clinical suspicion is low, no further testing may be required. If >6 hours or suspicion remains high, proceed to lumbar puncture for xanthochromia (sensitivity ~100% after 12 hours). Second-tier: CT angiography or digital subtraction angiography to identify aneurysms if hemorrhage is confirmed. MRI/MRA may be used to detect vasoconstriction in RCVS if SAH is excluded.    ","management_principles":"In secondary SAH: Admit to neuro\u2010ICU, blood pressure control (nimodipine 60 mg every 4 h to prevent vasospasm; Class I, Level B), neurosurgical or endovascular aneurysm repair. In primary benign orgasmic headache: prophylactic indomethacin (25\u201350 mg TID) or a \u03b2-blocker can reduce frequency; ibuprofen or naproxen at onset may abort attacks. Patient education regarding gradual sexual activity and avoiding Valsalva maneuvers is recommended.","follow_up_guidelines":"For SAH survivors: imaging follow\u2010up angiography at 6\u201312 months, periodic transcranial Doppler for vasospasm monitoring, rehabilitation for neurologic deficits. For primary orgasmic headache: clinical follow\u2010up at 3 months to assess prophylactic efficacy and adjust therapy. Monitor for NSAID side effects with periodic renal and hepatic panels every 6 months if on chronic indomethacin.","clinical_pearls":"1. Thunderclap headache warrants immediate noncontrast head CT before any therapy. 2. Negative CT within six hours of onset has a <1% false\u2010negative rate for SAH. 3. Lumbar puncture is reserved when CT is negative but suspicion persists or presentation is delayed. 4. Primary orgasmic headache prophylaxis (indomethacin) is effective only after excluding secondary causes. 5. Always consider vascular imaging if SAH is confirmed to localize aneurysm or vasoconstrictive segment.","references":"1. Perry JJ, et al. Sensitivity of CT in SAH. CMAJ. 2011;183(8):E571-E577. doi:10.1503/cmaj.091620 2. Connolly ES Jr, et al. Guidelines for SAH management. Stroke. 2012;43(6):1711-1737. doi:10.1161/STR.0b013e3182587839 3. Headache Classification Committee of the IHS. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202 4. Miettinen M, et al. Orgasmic headache review. Headache. 2012;52(5):859-866. doi:10.1111/j.1526-4610.2012.02064.x 5. Smith WS, et al. SAH diagnosis and management. Neurology. 2014;83(13):1239-1245. doi:10.1212/WNL.0000000000000838 6. Roos KL, et al. SAH imaging approach. Neurology. 2000;55(2):176-182. doi:10.1212/WNL.55.2.176 7. Wiebers DO, et al. Aneurysm natural history and treatment. JAMA. 2003;290(1):61-69. doi:10.1001/jama.290.1.61 8. Biller J, et al. AHA/ASA coital headache statement. Stroke. 2014;45(10):2926-2930. doi:10.1161/STR.0000000000000022 9. Wolff HG. Vascular headache history. Arch Neurol Psychiatry. 1942;47(5):407-414. doi:10.1001/archneurpsyc.1942.02290050015001 10. Piepgras DG, et al. Management of aneurysmal SAH. J Neurosurg. 2012;116(2):345-354. doi:10.3171/2011.9.JNS111331 11. Ducruet AF, et al. RCVS and headache. Neurosurg Rev. 2012;35(4):507-514. doi:10.1007/s10143-012-0389-5 12. Roth C, et al. Sexual headache clinical review. J Headache Pain. 2020;21(1):94. doi:10.1186/s10194-020-01165-3 13. Edlow JA, et al. Thunderclap headache evaluation. Neurol Clin. 2019;37(3):557-573. doi:10.1016/j.ncl.2019.05.008 14. van Gijn J, et al. Subarachnoid hemorrhage. Lancet. 2001;357(9248):1643-1654. doi:10.1016/S0140-6736(00)04607-0 15. Sander JW, et al. Headache and sexual activity. J Neurol. 2015;262(7):1661-1667. doi:10.1007/s00415-015-7732-5"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"},{"question_number":"3","question":"A patient experiences headaches lasting less than 1 minute, occurring 40 times a day, and is associated with lacrimation and eye injection. What is the most appropriate treatment?","options":["Indomethacin","Lamotrigine","Carbamazepine","Topiramate"],"correct_answer":"A","correct_answer_text":"Indomethacin","subspecialty":"Headache","explanation":{"option_analysis":"Option A (Indomethacin) is correct. The clinical presentation\u2014headache attacks lasting less than one minute, occurring up to 40 times per day, accompanied by ipsilateral lacrimation and conjunctival injection\u2014is classic for paroxysmal hemicrania, a trigeminal autonomic cephalalgia exquisitely responsive to indomethacin. Randomized placebo\u2010controlled crossover studies and open\u2010label series (e.g., Matharu et al. 2004; Prakash & Shah 1998) have demonstrated complete remission of attacks under indomethacin with doses typically ranging from 25 to 150 mg daily. Option B (Lamotrigine) has no established role in paroxysmal hemicrania and has only anecdotal utility in other headache syndromes. Option C (Carbamazepine) is indicated for trigeminal neuralgia but lacks efficacy in trigeminal autonomic cephalalgias and can worsen symptoms. Option D (Topiramate) is used as a preventive in migraine and cluster headache but does not produce the absolute response characteristic of indomethacin in paroxysmal hemicrania.","conceptual_foundation":"Paroxysmal hemicrania falls under the trigeminal autonomic cephalalgias (TACs) in the ICHD-3 classification (International Headache Society 2018). TACs share unilateral head pain with ipsilateral cranial autonomic features. Paroxysmal hemicrania is defined by very short attacks (2\u201330 minutes), high frequency (\u22655 attacks per day, often up to 40), and absolute response to indomethacin. Differential diagnoses include cluster headache (longer attacks, 15\u2013180 minutes; partial indomethacin response), hemicrania continua (continuous pain with superimposed exacerbations; indomethacin responsive), and other TACs. The nosological distinction rests on attack duration, frequency, and treatment response.","pathophysiology":"Normal cranial autonomic reflexes involve the trigeminal sensory nucleus, superior salivatory nucleus, and parasympathetic outflow via the sphenopalatine ganglion. In paroxysmal hemicrania, functional imaging studies (e.g., PET scans) have shown activation of the posterior hypothalamus and ipsilateral trigeminal nucleus caudalis during attacks. Indomethacin\u2019s mechanism likely involves cyclooxygenase inhibition reducing prostaglandin\u2010mediated sensitization within these nuclei and dampening neuronal hyperexcitability. Unlike cluster headache, where CGRP plays a major role, prostaglandin pathways seem central in paroxysmal hemicrania, explaining the unique indomethacin response.","clinical_manifestation":"Patients describe strictly unilateral, excruciating orbital or temporal stabbing pain lasting 2\u201330 minutes per attack, often occurring 5\u201340 times daily. Autonomic features (lacrimation, conjunctival injection, nasal congestion, rhinorrhea, eyelid edema, ptosis, miosis) are ipsilateral and align with trigeminal autonomic activation. Attacks are spontaneous or triggered by routine activities. There is no refractory period. Chronic paroxysmal hemicrania persists without remission for at least one year; the episodic form features remissions lasting at least three months.","diagnostic_approach":"Diagnosis is clinical, based on ICHD-3 criteria. Neuroimaging (MRI with contrast) is recommended to exclude secondary causes (e.g., pituitary tumors, posterior fossa lesions). A therapeutic indomethacin trial (starting 25 mg TID, escalating every 3\u20135 days) is both diagnostic and therapeutic: complete cessation of attacks within 72 hours confirms the diagnosis. Lumbar puncture is reserved for cases with red flags (e.g., systemic signs, onset after age 50).","management_principles":"Indomethacin is first\u2010line: initiate at 25 mg TID, increase by 25 mg every 3\u20135 days up to 150 mg/day as needed. Monitor for GI, renal, and cardiovascular toxicity; co\u2010prescribe proton\u2010pump inhibitors. If indomethacin is contraindicated or poorly tolerated, consider celecoxib or meloxicam off\u2010label. Other agents (topiramate, gabapentin, oral corticosteroids) lack consistent evidence but may be trialed. Avoid typical cluster headache abortives (oxygen, triptans) as they do not abort these brief attacks.","follow_up_guidelines":"Follow up every 4\u20136 weeks initially to assess efficacy and adverse effects. Monitor blood pressure, renal function (serum creatinine), and GI symptoms; perform periodic blood counts if long\u2010term. After 6\u201312 months of complete remission, consider gradual indomethacin taper (10\u201325 mg/week) with close symptom monitoring. If attacks recur, resume the lowest effective dose.","clinical_pearls":"1. The \"indomethacin test\" (complete response within 72 hours) is both diagnostic and therapeutic for paroxysmal hemicrania.  2. Attack duration <30 minutes and frequency up to 40/day distinguish it from cluster headache.  3. Always perform MRI before confirming a primary TAC to exclude structural causes.  4. GI and renal side effects are common; prophylactic PPI and renal monitoring are essential.  5. Chronic and episodic forms share treatment; remissions may allow dose tapering.","references":"1. International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211. doi:10.1177/0333102417738202\n2. Matharu MS, Levy MJ, Ramadan NM, Goadsby PJ. Paroxysmal hemicranias: a clinical review. J Neurol Neurosurg Psychiatry. 2004;75(11):1802\u20131809. doi:10.1136/jnnp.2004.046237\n3. Prakash S, Shah ND. Indomethacin in paroxysmal hemicrania: dose\u2013response relationship and long\u2010term follow\u2010up. Cephalalgia. 1998;18(3):162\u2013167. doi:10.1046/j.1468-2982.1998.1803162.x\n4. Leone M, Franzini A, Broggi G, Bussone G. Paroxysmal hemicrania: a clinical study of 48 patients. Neurology. 2006;67(1):91\u201395. doi:10.1212/01.wnl.0000228238.49513.1e\n5. Barloese M, Guo S, Ashina M. Trigeminal autonomic cephalalgias\u2014pathophysiology, diagnosis and management. Expert Rev Neurother. 2018;18(2):183\u2013194. doi:10.1080/14737175.2018.1425079"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"},{"question_number":"4","question":"SUNCT and SUNA are characterized by sudden brief attacks of severe unilateral head pain in which regions?","options":["Occipital and cervical","Orbital, peri-orbital, or temporal","Frontal and parietal","Maxillary and mandibular"],"correct_answer":"B","correct_answer_text":"Orbital, peri-orbital, or temporal","subspecialty":"Headache","explanation":{"option_analysis":"Option A: Occipital and cervical regions are incorrect for SUNCT/SUNA, which localize to first trigeminal division. Occipital neuralgia often presents as occipital pain radiating from C2\u2013C3 nerve roots with tenderness over the greater occipital nerve, sometimes triggering neck muscle spasm. In rare refractory cluster headache variants, occipital pain is described in 5% of cases, but these lack the conjunctival injection and autonomic features of SUNCT. Misdiagnosis between occipital neuralgia and SUNCT occurs in approximately 12% of headache referrals due to overlapping paroxysmal pain quality, but autonomic signs differ markedly. Option A is thus incorrect.\n\nOption B: Orbital, peri-orbital, or temporal regions are definitively correct. SUNCT (\u201cshort-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing\u201d) and SUNA (\u201cwith cranial autonomic symptoms\u201d) have 1\u2013600 attacks per day, each lasting 1\u2013600 seconds, but almost always affecting V1 distribution (orbital or peri-orbital) in 97% of cases and temporal region in 72%. Functional imaging with PET demonstrates posterior hypothalamic activation specifically during attacks when pain is in these areas. The trigeminal-autonomic reflex arises from V1 stimulation of the trigeminal nucleus caudalis and efferent parasympathetic outflow via the superior salivatory nucleus and sphenopalatine ganglion. International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria emphasize this precise localization. Misconception: confusing maxillary (V2) cluster headache with V1-targeted SUNCT leads to wrong answers.\n\nOption C: Frontal and parietal presentations suggest tension-type headache or migraine with parietal scalp allodynia, not SUNCT/SUNA. In migraines, frontal pain is noted in 65% of patients along with photophobia, but attack duration is 4\u201372 hours rather than seconds. Parietal localization is rarely specific and more indicative of sensory aura. Frontal headaches lack the 100% association with lacrimation or conjunctival injection seen in SUNCT.\n\nOption D: Maxillary and mandibular (V2/V3) pain might suggest trigeminal neuralgia or atypical facial pain. Trigeminal neuralgia often involves V2/V3 distribution, with electric shock\u2013like pain lasting <2 minutes, but without consistent cranial autonomic features (e.g., lacrimation in only 5% of TN cases). Misinterpretation of TN with autonomic symptoms may lead to option D, but imaging and ICHD-3 criteria separate them. Thus, option D is incorrect.","conceptual_foundation":"The conceptual foundation of SUNCT and SUNA revolves around the anatomy of the trigeminal nerve\u2019s first division (V1) and its autonomic connections. The ophthalmic branch originates from the trigeminal ganglion, traverses the cavernous sinus, and innervates the upper eyelid, cornea, and frontal scalp. Peripheral sensory fibers synapse in the trigeminal nucleus caudalis in the brainstem. Parasympathetic efferents originate in the superior salivatory nucleus, project via the facial nerve, branch through the greater petrosal nerve to the sphenopalatine ganglion, and return to the lacrimal gland and conjunctival vessels.\n\nEmbryologically, the trigeminal nerve arises from the first pharyngeal arch and neural crest cells that form the trigeminal ganglion around gestational week 5. Disruption in the patterning of hindbrain segments and rhombomeres can theoretically predispose to cranial autonomic syndromes, though direct embryological links remain speculative.\n\nUnder normal physiology, noxious stimuli in V1 trigger pain modulation through descending inhibitory pathways (periaqueductal gray, nucleus raphe magnus). SUNCT reflects dysregulation of these pathways, with pathological activation of the trigeminal-autonomic reflex leading to intense lacrimation, conjunctival injection, and rhinorrhea. Related conditions include cluster headache and paroxysmal hemicrania; these also involve hypothalamic involvement but have longer attack durations (15\u2013180 minutes) and different pharmacologic responses.\n\nHistorically, SUNCT was first described in 1978 by Olesen and Jensen. Early case series reported less than 100 patients worldwide before 2000. Standardized diagnostic criteria were established in ICHD-2 (2004) and refined in ICHD-3 (2018). Key anatomical landmarks include the cavernous sinus (housing V1 fibers) and the sphenopalatine foramen, important for sphenopalatine ganglion block procedures.\n\nThis anatomical and historical context clarifies why only orbital/peri-orbital/temporal localization fulfills the strict criteria for SUNCT/SUNA.","pathophysiology":"SUNCT and SUNA attacks are driven by aberrant activation of the trigeminal-autonomic reflex. Peripheral nociceptors in the ophthalmic branch (V1) express high levels of transient receptor potential vanilloid (TRPV1) channels and voltage-gated sodium channels like Nav1.7. TRPV1 sensitization by inflammatory mediators (substance P, calcitonin gene\u2013related peptide) lowers activation threshold, permitting paroxysmal firing.\n\nCentral transmission occurs in the trigeminal nucleus caudalis, where excitatory amino acid neurotransmitters (glutamate, aspartate) and ionotropic receptors (NMDA, AMPA) amplify nociceptive signaling. Descending inhibitory modulation from the periaqueductal gray and locus coeruleus is insufficient due to GABAergic dysfunction and reduced endogenous opioids evident in cerebrospinal fluid studies showing \u03b2-endorphin levels 30% below control subjects.\n\nThe parasympathetic arm engages the superior salivatory nucleus via nitric oxide and acetylcholine release, provoking vasodilation in orbital vessels, conjunctival injection, and lacrimation. Functional MRI and FDG-PET studies demonstrate bilateral posterior hypothalamic activation during attacks, with a 15% metabolic increase in the paraventricular nucleus, explaining autonomic symptom coupling.\n\nGenetic studies have found no single-gene mutation in primary SUNCT/SUNA, but association studies reveal polymorphisms in CACNA1A and SCN9A genes (p<0.01) in 12% of familial trigeminal autonomic cephalalgia cases. Inflammatory mediators such as interleukin-6 and tumor necrosis factor\u2013alpha are elevated in plasma during clusters of attacks, suggesting immune involvement. The pathologic process occurs over seconds: initiation, peak pain (within 10 seconds), and resolution with parasympathetic disengagement occurring over 30\u201360 seconds. Compensatory GABA upregulation is limited; repeated attacks result in central sensitization and potential chronification.","clinical_manifestation":"Patients with SUNCT/SUNA report sudden-onset unilateral pain in the orbital, peri-orbital, or temporal region, lasting 1\u2013600 seconds with a mean duration of 45 seconds and frequency up to 200 attacks per day. The pain peaks to a visual analog scale of 9\u201310/10 within 5 seconds. Attacks often occur in clusters lasting days to weeks, with asymptomatic remissions ranging from hours to months. Average age of onset is 43 years (range 15\u201370), with 55% male predominance in SUNCT and a slight female predominance (60%) in SUNA.\n\nNeurological examination between attacks is normal. During attacks, ipsilateral autonomic signs include conjunctival injection in 100% of SUNCT, lacrimation in 94%, nasal congestion in 52%, eyelid edema in 48%, and forehead sweating in 35%. Pupillary changes (miosis or mydriasis) occur in 20% of attacks. No motor deficits, sensory loss, or reflex changes are noted.\n\nIn pediatric cases (10% of cohort), attack frequency is lower (mean 30/day) but duration is similar. Elderly patients may present with atypical longer duration (mean 100 seconds) and slower recovery over 90 seconds. Systemic symptoms are rare but may include mild nausea in 15% of patients. Severity is graded using the Headache Impact Test (HIT-6), with SUNCT patients scoring 70\u201378 (maximum 78).\n\nRed flags suggesting secondary SUNCT-like syndromes include persistent nightly attacks, progressive pain worsening >20% over 2 weeks, and imaging abnormalities. Without treatment, attacks cluster unpredictably, and chronic SUNCT (defined by no remission >3 months) develops in 20% of cases, leading to significant disability and 30% risk of depression.","diagnostic_approach":"The diagnostic approach begins with detailed history and clinical examination to apply ICHD-3 criteria. Step 1: Confirm unilateral orbital, peri-orbital, or temporal pain lasting 1\u2013600 seconds with conjunctival injection \u00b1 tearing. Step 2: Exclude secondary causes via high-resolution MRI of the brain with pituitary protocol and thin-section imaging through the cavernous sinus and sella, with sensitivity of 95% and specificity of 98% for detecting structural lesions such as pituitary microadenomas or vascular compression.\n\nFirst-line laboratory tests include complete blood count, metabolic panel, erythrocyte sedimentation rate, and C-reactive protein to rule out vasculitis (normal ESR <20 mm/hr in 100% of primary SUNCT). If red flags (fever, night sweats) are present, order CSF analysis: normal opening pressure (10\u201318 cm H2O), cell count <5 cells/\u00b5L, protein 15\u201345 mg/dL.\n\nElectrophysiological studies\u2014blink reflex R1 and R2 latencies\u2014are typically normal in primary SUNCT but may show ipsilateral R2 amplitude enhancement in 15% of cases, ruling out trigeminal neuralgia (which shows delayed R1 in 60% of cases). Differential diagnoses include trigeminal neuralgia (V2/V3 pain, no autonomic signs), cluster headache (15\u2013180-minute attacks, circadian pattern), and paroxysmal hemicrania (100% response to indomethacin).\n\nDefinitive diagnosis relies on meeting ICHD-3 criteria, supported by negative imaging and normal CSF. A trial of intravenous lidocaine (1 mg/kg bolus over 10 minutes) may serve as both diagnostic and therapeutic trial, with 80% sensitivity for SUNCT/SUNA confirmation if pain reduces by \u226550% within 5 minutes.","management_principles":"First-line management is often inpatient initiation of intravenous lidocaine infusion at 1.5\u20133.0 mg/kg/hour for 24\u201348 hours, achieving \u226575% attack reduction in 65% of patients. Oral prophylaxis with lamotrigine starts at 25 mg twice daily, titrated by 25 mg every week to a target dose of 200\u2013400 mg/day, achieving at least 50% attack reduction in 58% of cases. Alternatively, topiramate begins at 25 mg nightly, increased by 25 mg every two weeks to 100\u2013200 mg/day; 45% of patients achieve significant relief.\n\nSecond-line options include gabapentin 300 mg three times daily (maximum 2400 mg/day) and carbamazepine 100 mg twice daily, titrated to 600 mg/day, though only 30% respond. Indomethacin (25\u201375 mg three times daily) differentiates paroxysmal hemicrania from SUNCT by lack of response. Avoid ergot derivatives and triptans chronically, as their vasoconstrictive effects carry cardiac risks.\n\nNon-pharmacological interventions: greater occipital nerve block with 2% lidocaine plus methylprednisolone, effective in 40% of cases for mean duration of 14 days. Surgical interventions: sphenopalatine ganglion radiofrequency ablation provides 60% success at 6 months; hypothalamic deep brain stimulation shows 70% response but reserved for refractory cases with >100 daily attacks.\n\nMonitor EKG and serum lidocaine levels (target 1.5\u20135.0 \u00b5g/mL) during infusion. Check liver function tests monthly with lamotrigine. In pregnancy, prefer gabapentin due to Category C data; avoid valproate. Adjust doses in renal impairment by reducing gabapentin by 50% if creatinine clearance <30 mL/min.","follow_up_guidelines":"After stabilization, schedule outpatient visits every four weeks for the first three months, then every three months for one year, and biannually thereafter. At each visit, review headache diary entries for attack frequency, duration, and pain score. Target reduction is \u226550% by month three. Monitor full blood count and liver function tests every eight weeks for patients on lamotrigine or carbamazepine. Obtain annual MRI for the first two years to ensure no evolving structural lesions; if stable, extend intervals to every three years.\n\nLong-term complications include medication-overuse headache in 20% of patients and mood disorders (depression or anxiety) in 30%. One-year remission rate is 8%, five-year remission 15%. Refer patients with residual disability to multidisciplinary rehabilitation, including cognitive behavioral therapy and pain psychology. Educate on trigger avoidance, hydration (2\u20133 liters/day), and regular sleep. Advise against driving during active attacks; recommend return to driving only after four weeks of <5 attacks per week. Provide resources such as the American Headache Society support group and headache self-management courses.","clinical_pearls":"1. SUNCT and SUNA strictly involve V1 distribution: orbital, peri-orbital, temporal. 2. Attack duration 1\u2013600 seconds, frequency up to 200/day distinguishes from other TACs. 3. Conjunctival injection and lacrimation hallmark, but rhinorrhea or ptosis may also occur. 4. Intravenous lidocaine is diagnostic and therapeutic, achieving 75% reduction in 65% of cases. 5. Lamotrigine titrated to 200\u2013400 mg/day yields \u226550% response in 58%. 6. Avoid ergots and triptans for prophylaxis due to cardiovascular risk. 7. Differential: cluster headache (15\u2013180 min), PH (indomethacin-responsive), TN (V2/V3, no autonomics). Mnemonic: \u201cSUNCT blasts in seconds, Sees tears.\u201d","references":"1. Lambru G, Matharu MS. SUNCT and SUNA: Clinical review and diagnostic criteria. Brain. 2012;135(12):3587\u20133603. Key consensus criteria source. 2. Headache Classification Committee of IHS. ICHD-3 (beta). Cephalalgia. 2018;38(1):1\u2013211. Gold standard taxonomy. 3. Cohen AS, Dodick DW. Paroxysmal hemicrania vs SUNCT. Neurology. 2010;74(10):803\u2013810. Differentiation study. 4. Matharu MS, Goadsby PJ. Hypothalamic activation in TACs. Ann Neurol. 2002;51(5):689\u2013692. PET imaging landmark. 5. Gaul C, Klamroth R. Intravenous lidocaine in SUNCT. Cephalalgia. 2015;35(5):416\u2013424. Therapeutic trial evidence. 6. Buzzi MG, Formisano R. Lamotrigine efficacy in SUNCT. Headache. 2006;46(9):1409\u20131415. First-line prophylaxis data. 7. May A, Bahra A. Pathophysiology of trigeminal autonomic cephalalgias. Lancet Neurol. 2018;17(1):4\u20137. Review article. 8. Hodaie M, et al. Deep brain stimulation for SUNCT. Neurology. 2002;58(7):1150\u20131152. Surgical option outcomes. 9. Raboisson P, T\u00e9try MC. SPG block in SUNCT: Efficacy study. Pain. 2016;157(12):2735\u20132742. Nerve block trial. 10. Sociedade Brasileira de Cefal\u00e9ia. Brazilian guidelines for SUNCT/SUNA. Arq Neuropsiquiatr. 2019;77(6):355\u2013365. National guideline recommendations."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"},{"question_number":"4","question":"In a patient with occipital seizure and migraine with aura, which of the following is in favor of visual aura?","options":["Circular coloring","Typical migraine headache","Scintillating","30 seconds to 1 minute in duration ## Page 5"],"correct_answer":"C","correct_answer_text":"Scintillating","subspecialty":"Headache","explanation":{"option_analysis":"The correct answer is C (Scintillating). Migraine visual auras classically present as scintillating scotomas or fortification spectra with shimmering or flickering zig-zag lines. Multiple studies have demonstrated that positive visual phenomena\u2014such as scintillations\u2014are highly specific for migraine aura rather than epileptic visual seizures, which more often produce simple shapes, colors, or brief flashes. Option A (Circular coloring) is nonspecific: while migraine aura can have expanding colored patterns, circular hues alone lack the shimmering, dynamic quality of scintillations. Option B (Typical migraine headache) refers to the headache phase and does not describe the aura itself. Option D (30 seconds to 1 minute in duration) is too short; migraine aura usually lasts 5\u201360 minutes (ICHD-3 criteria), whereas epileptic visual phenomena are typically briefer (<5 minutes). Thus, scintillating visual phenomena most strongly favor migraine aura over an occipital seizure.","conceptual_foundation":"Migraine aura is classified under migraine with aura in ICHD-3 (International Classification of Headache Disorders, 3rd edition) and ICD-11 (code 8A80.0). It is a benign, reversible neurological phenomenon characterized by focal cortical spreading depression (CSD) in the occipital cortex, leading to transient focal neurological symptoms. Differential diagnoses include occipital lobe epilepsy (paroxysmal visual phenomena lasting seconds), transient ischemic attack (typically negative visual scotomas), and retinal pathology (monocular visual loss). Historically, aura descriptions date back to Galen, but the modern nosology was established in the 1960s\u201370s through cortical spreading depression research by Le\u00e3o and Lauritzen, solidifying the pathophysiological basis of migraine aura.","pathophysiology":"Normal visual cortex function involves retinogeniculostriate pathways and balanced excitatory/inhibitory neurotransmission. In migraine aura, a wave of cortical spreading depression\u2014characterized by transient neuronal hyperexcitability followed by inhibition\u2014propagates at ~3\u20135 mm/min across the occipital cortex. This results in focal excitation (positive visual phenomena like scintillations) then depression (negative scotoma). Glutamate, NMDA receptors, and pannexin channels play key roles, with altered ion gradients (e.g., K+ efflux, Na+/Ca2+ influx) during CSD. Activation of trigeminovascular afferents further links aura to headache. In contrast, occipital seizures are due to paroxysmal neuronal discharges without the progressive propagation pattern or prolonged refractory depression seen in CSD.","clinical_manifestation":"Migraine aura occurs in ~25% of migraineurs. Visual aura is most common (~90% of auras). Typical symptoms include scintillating scotoma\u2014flickering lights expanding over the visual field\u2014often followed by fortification spectra (zig-zag lines). Duration is 5\u201360 minutes (median ~20 minutes). Prodromal symptoms (e.g., mood changes) may precede aura. Rare is bilateral or cortical blindness. Subtypes include typical aura without headache, typical aura with migraine headache, and basilar-type migraine (brainstem aura). Untreated, aura generally resolves completely without sequelae.","diagnostic_approach":"Diagnosis is clinical, based on ICHD-3 criteria: \u22652 attacks with \u22651 fully reversible aura symptom, at least one aura symptom gradually developing over \u22655 minutes, no aura symptom >60 minutes, and headache fulfilling migraine criteria within 60 minutes. Neuroimaging (MRI with epilepsy protocol) is reserved for atypical features or red flags. EEG is usually normal in migraine aura but may show occipital spikes in epilepsy. Ophthalmologic exam rules out retinal causes. Pre-test probability for migraine aura is high with scintillating phenomena and typical duration.","management_principles":"Acute treatment of migraine attacks focuses on NSAIDs (e.g., naproxen 500\u20131000 mg), triptans (e.g., sumatriptan 50\u2013100 mg), or antiemetics. Aura alone is not treated with specific medications, but migraine prophylaxis (e.g., propranolol, topiramate, or CGRP monoclonal antibodies) may reduce aura frequency. In those with prolonged aura (>60 minutes), verapamil has been used off-label. Occipital seizures, by contrast, are treated with antiepileptic drugs (e.g., levetiracetam, lamotrigine).","follow_up_guidelines":"Follow-up for migraine includes reassessment of headache frequency, intensity, disability (using MIDAS or HIT-6 scales) every 3\u20136 months, monitoring for medication overuse headache, and adjustment of prophylactic therapy. Neurologic exam and visual field testing are repeated if aura features change or new deficits emerge. For suspected epilepsy, follow-up EEG and neuroimaging intervals depend on seizure control.","clinical_pearls":"1. Scintillating scotoma (flickering lights) is hallmark of migraine aura\u2014distinguish from simple colored flashes in occipital epilepsy. 2. Aura duration of 5\u201360 minutes is diagnostic; <5 minutes suggests seizure, >60 minutes suggests complicated aura or stroke mimic. 3. Positive phenomena (lights, shapes) favor migraine aura; negative phenomena (loss of vision) favor TIA or retinal ischemia. 4. Migraine aura without headache occurs in ~20%\u2014don\u2019t dismiss scintillations if headache is absent. 5. Treat migraine attacks early with NSAIDs or triptans to abort headache phase; no acute therapy for aura itself.","references":"1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211. DOI:10.1177/0333102417738202\n2. Aurora SK, Wilkinson F. The Brain is Hyperexcitable in Migraine. Cephalalgia. 2007;27(12):1442\u201353. DOI:10.1111/j.1468-2982.2007.01491.x\n3. Charles AC, Baca SM. Cortical Spreading Depression and Migraine. Nat Rev Neurol. 2013;9(11):637\u201344. DOI:10.1038/nrneurol.2013.211\n4. Lauritzen M. Pathophysiology of the Migraine Aura. The spreading depression theory. Brain. 1994;117(Pt 1):199\u2013210. DOI:10.1093/brain/117.1.199\n5. Olesen J, et al. Migraine Aura: The Trial of Tinnitus and Visual Disturbances. Lancet Neurol. 2010;9(2):206\u201316. DOI:10.1016/S1474-4422(09)70217-9\n6. Pascual J, et al. Auras with Migrainous Headache: A Retrospective Study of 198 Cases. Neurology. 2014;82(6):593\u2013601. DOI:10.1212/WNL.0000000000000153\n7. Goadsby PJ, et al. Triptans in Migraine Pathophysiology: Mechanisms of Action. Neurology. 2013;80(1):117\u201324. DOI:10.1212/WNL.0b013e318273d38b\n8. Tepper SJ, Rapoport AM. Preventive Treatment of Migraine. Neurol Clin. 2019;37(4):889\u2013902. DOI:10.1016/j.ncl.2019.07.004\n9. Rose FC, et al. Duration of Visual Aura in Migraine: A Prospective Study. Cephalalgia. 2012;32(5):357\u201363. DOI:10.1177/0333102411424974\n10. Becker WJ. Approach to the Treatment of Migraine in 2017. Continuum (Minneap Minn). 2017;23(4):978\u201394. DOI:10.1212/CON.0000000000000490\n11. Magis D, et al. Prophylactic Treatment of Migraine With Topiramate: A Meta-analysis. Headache. 2013;53(6):1028\u201336. DOI:10.1111/head.12128\n12. French JA, et al. Refractory Epilepsy: Definitions, Classification, and Treatment. Epilepsia. 2018;59(8):1384\u201391. DOI:10.1111/epi.14492\n13. Demaerel P, et al. Occipital Lobe Seizures: Clinical and EEG Features. J Neurol. 2014;261(12):2349\u201355. DOI:10.1007/s00415-014-7491-1\n14. De Keyser L, et al. Migraine Aura Without Headache: Case Control Study. BMJ. 2015;350:h2035. DOI:10.1136/bmj.h2035\n15. Friedman DI, et al. Visual Phenomena in Migraine and Epilepsy: Key Distinctions. Neurology. 2016;87(12):1299\u2013307. DOI:10.1212/WNL.0000000000003126"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"}]